¼¼°èÀÇ ½ÃÄö½º ŰƮ ½ÃÀå
Sequencing Kits
»óǰÄÚµå : 1742816
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 464 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,136,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,408,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ½ÃÄö½º ŰƮ ½ÃÀåÀº 2030³â±îÁö 192¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 129¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ½ÃÄö½º ŰƮ ½ÃÀåÀº 2024-2030³â¿¡ CAGR 6.9%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 192¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÇÙ»ê ÃßÃâ°ú ÁõÆøÀº CAGR 8.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 125¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¶óÀ̺귯¸® Á¶Á¦ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 4.6%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 35¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 11.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½ÃÄö½º ŰƮ ½ÃÀåÀº 2024³â¿¡ 35¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 40¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 11.0%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.3%¿Í 6.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ "½ÃÄö½º ŰƮ" ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

½ÃÄö½Ì ŰƮ°¡ À¯ÀüüÇÐ ¹× Á¤¹ÐÀÇ·áÀÇ Áß½ÉÀÌ µÇ´Â ÀÌÀ¯´Â?

½ÃÄö½Ì ŰƮ´Â DNA ¹× RNA ºÐ¼® ¿öÅ©Ç÷ο쿡 ÇʼöÀûÀÎ ±¸¼º ¿ä¼Ò·Î, À¯Àü ¹°ÁúÀÇ Áغñ, ÁõÆø ¹× µðÄÚµù¿¡ ÇÊ¿äÇÑ ½Ã¾à°ú ÇÁ·ÎÅäÄÝÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ Å°Æ®´Â ÀüÀåÀ¯Àüü ½ÃÄö½Ì, Ç¥Àû À¯ÀüÀÚ ÆÐ³Î, ÈļºÀ¯Àüü ÇÁ·ÎÆÄÀϸµ, ¸ÞŸÀ¯Àüü µî ´Ù¾çÇÑ ¿ëµµ¸¦ Áö¿øÇÕ´Ï´Ù. ÀÓ»ó Áø´Ü, Á¾¾çÇÐ ¿¬±¸, ³ó¾÷ »ý¸í°øÇÐ µî ´Ù¾çÇÑ ºÐ¾ß¿¡ °ÉÃÄ º¹ÀâÇÑ ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí ÀϰüµÈ °á°ú¸¦ º¸ÀåÇÏ´Â Á¶»ç ŰƮ¸¦ Á¦°øÇÕ´Ï´Ù. Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®±â(NGS)ÀÇ ¹ßÀüÀ¸·Î ÀÌ·¯ÇÑ Å°Æ®ÀÇ Á߿伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù. 󸮷®ÀÌ ³ôÀº Ç÷§ÆûÀº ¼öõ °³ÀÇ »ùÇÃÀ» È¿À²ÀûÀ¸·Î ó¸®Çϱâ À§ÇØ °íÃæ½Çµµ, Àú¿À¿° ½Ã¾àÀÌ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ ¼ÒºñÀÚ À¯ÀüüÇÐ, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È °Ë»ç, °¨¿°º´ °¨½ÃÀÇ ºÎ»óÀ¸·Î ½ÃÄö½Ì ŰƮ´Â ¿¤¸®Æ® ½ÇÇè½Ç»Ó¸¸ ¾Æ´Ï¶ó ºÐ»êÇü ¹× ÇöÀå Áø·á ȯ°æ¿¡¼­µµ »ç¿ëµÇ±â ½ÃÀÛÇß½À´Ï´Ù. ±× Ȱ¿ë¼º°ú À¯ÀüÀÚ Á¤º¸¸¦ ¹àÇô³»´Â ¿ªÇÒ·Î ÀÎÇØ Á¤¹ÐÀÇ·á ½Ã´ë¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù.

¶óÀ̺귯¸® Áغñ¿Í PCRÀÇ Çõ½ÅÀÌ Å°Æ®ÀÇ ÁøÈ­¸¦ ÃËÁøÇϴ°¡?

½ÃÄö½Ì ŰƮ´Â ±âº»ÀûÀÎ ½Ã¾à ¹øµé¿¡¼­ Á¤±³ÇÑ È¿¼Ò ÃÖÀûÈ­ Ç÷§ÆûÀ¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ¶óÀ̺귯¸® Áغñ ŰƮÀÇ Çõ½ÅÀº ÀÔ·Â DNAÀÇ ¾çÀ» ÁÙÀ̰í, ÀÚµ¿È­¸¦ °¡´ÉÇÏ°Ô Çϸç, ´ÜÆíÈ­µÈ »ùÇðú ¿­È­µÈ »ùÇÃÀ» Áö¿øÇϰí, PCRÀÌ ÇÊ¿ä ¾ø´Â ¿öÅ©Ç÷ο찡 ÁõÆø ÆíÇâÀ» ÃÖ¼ÒÈ­Çϰí, µà¾ó À妽º ¾î´ðÅͰ¡ Á¤È®µµ¸¦ ÀúÇϽÃŰÁö ¾Ê°í ´ÙÁßÈ­¸¦ ÃËÁøÇÕ´Ï´Ù. Á¤È®µµ¸¦ ¶³¾î¶ß¸®Áö ¾Ê°í ´ÙÁßÈ­¸¦ ÃËÁøÇÕ´Ï´Ù. È¿¼Ò °­È­·Î ¹ÝÀÀ ½Ã°£ ´ÜÃà, ƯÀ̼º Çâ»ó, ¹é±×¶ó¿îµå ³ëÀÌÁî ÃÖ¼ÒÈ­µµ ½ÇÇöÇß½À´Ï´Ù. ´ÜÀÏ ¼¼Æ÷ ½ÃÄö½Ì ŰƮ, ·Õ ¸®µå ½ÃÄö½Ì ½Ã¾à, ¸Þƿȭ ƯÀÌÀû Àüó¸® ŰƮ´Â ÀÌ ±â¼úÀÇ ¹üÀ§¸¦ »õ·Î¿î »ý¹°ÇÐÀû ¿µ¿ªÀ¸·Î È®ÀåÇϰí ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀÌ Èñ±Í º¯Á¾, º¹ÀâÇÑ ±¸Á¶Àû µ¹¿¬º¯ÀÌ, ¼¼Æ÷ ƯÀÌÀû ¹ßÇö ÆÐÅÏÀ» Á¶»çÇϰíÀÚ ÇÒ ¶§, ŰƮ ÇÁ·Î¹ÙÀÌ´õµéÀº ¸ÂÃãÇü °í¼º´É È­Çй°Áú·Î ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ »çÀü ÃæÀüµÈ īƮ¸®Áö, µ¿°á°ÇÁ¶ ½Ã¾à, ½Ç¿Â¿¡¼­ ¾ÈÁ¤µÈ Æ÷¸ËÀº ƯÈ÷ ÇöÀå Áø´Ü ¹× À̵¿½Ä ½ÇÇè½Ç ȯ°æ¿¡¼­ Ãë±Þ ¹× ¿î¼ÛÀ» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù.

±ÔÁ¦¿Í ÀÓ»ó ÅëÇÕÀº ŰƮ µðÀÚÀÎÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

½ÃÄö½ÌÀÌ ºñħ½ÀÀû »êÀü°Ë»ç(NIPT), Á¾¾çÇÐ µ¿¹Ý Áø´Ü, º´¿øÃ¼ À¯Àüü ÃßÀû µî ±ÔÁ¦ ´ë»ó ÀÓ»ó Áø´ÜÀ¸·Î È®ÀåµÊ¿¡ µû¶ó ½ÃÄö½Ì ŰƮ´Â ´õ¿í ¾ö°ÝÇÑ Ç¥ÁØÈ­¿Í °ËÁõÀ» ¹Þ°í ÀÖ½À´Ï´Ù. °³¹ß¾÷üµéÀº ÇöÀç FDA, CE-IVDR ¹× ±âŸ ±¹°¡ÀÇ ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇÏ´Â IVD µî±Þ ŰƮ¸¦ °³¹ßÇϰí ÀÖ½À´Ï´Ù. ¿©±â¿¡´Â »çÀü °ËÁõµÈ ¿öÅ©Ç÷οì, ÃßÀû¼º, ½Ã¾à ·ÎÆ® °£ Àϰü¼º µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ Å°Æ®´Â ¿£µåÅõ¿£µå ȣȯ¼ºÀ» º¸ÀåÇÏ°í ¿öÅ©ÇÃ·Î¿ì ¿À·ù¸¦ ÁÙÀ̱â À§ÇØ ½ÃÄö½Ì Ç÷§Æû°ú °øµ¿À¸·Î °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÓ»ó °Ë»ç Á¤º¸ ½Ã½ºÅÛ(LIS) ¹× ÀÚµ¿ ¸®Äûµå Çڵ鷯¿ÍÀÇ ÅëÇÕµµ CLIA ÀÎÁõ ½ÇÇè½Ç ¹× º´¿ø ±â¹Ý ½ÇÇè½Ç¿¡ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·áºñ º¸»ó°ú ¿¬°èµÈ Áø´ÜÀº °³¹ßÀڵ鿡°Ô È¿À²¼º Çâ»ó°ú »ùÇÃ´ç ºñ¿ë Àý°¨À» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÓ»ó ¿ëµµ´Â Á¶»ç Åø¿¡¼­ ÀÇ·á ¿öÅ©Ç÷οìÀÇ Áß¿äÇÑ ÀÎÁõ °¡´ÉÇÑ ±¸¼º ¿ä¼Ò·Î º¯¸ðÇϰí ÀÖÀ¸¸ç, ´õ ³ôÀº Á¦Á¶ Ç¥ÁØ, ´õ ³ªÀº ±â¼ú Áö¿ø ¹× ÄÄÇöóÀ̾𽺠¹®¼­È­¿¡ ´ëÇÑ °­Á¶°¡ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

½ÃÄö½Ì ŰƮ ½ÃÀåÀÇ ¼¼°è ¼ºÀå µ¿·ÂÀº?

¼¼°èÀǽÃÄö½Ì ŰƮ½ÃÀå ¼ºÀåÀº À¯Àüü ¿¬±¸ºñ Áõ°¡, NGSÀÇ ÀÓ»ó µµÀÔ, ½ÃÄö½Ì È­ÇÐÀÇ Çõ½Å µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¹Ì±¹, Áß±¹, ¿µ±¹, Áßµ¿¿¡¼­ ±¹°¡ Â÷¿øÀÇ À¯Àüü ¿¬±¸ ±¸»óÀÌ È®´ëµÊ¿¡ µû¶ó °íǰÁúÀÇ ºñ¿ë È¿À²ÀûÀΠŰƮ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¾¾çÇÐ, Èñ±ÍÁúȯ Áø´Ü, °¨¿°¼º Áúȯ °¨½Ã(ƯÈ÷ COVID ÀÌÈÄ)¿¡¼­ ½ÃÄö½ÌÀÇ ÅëÇÕÀ¸·Î Ç¥ÁØÈ­µÈ °ËÁõµÈ ŰƮ´Â ÀÓ»ó ½ÇÇè½Ç¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. Çмú±â°ü, CRO ¹× Á¦¾à ȸ»ç´Â ½ÃÄö½Ì ±â¹Ý Ž»ö ÇÁ·Î±×·¥À» È®ÀåÇϰí ÀÖÀ¸¸ç ´Ù¾çÇÑ Æ¯¼ö ½Ã¾à ŰƮ¸¦ ÇÊ¿ä·Î Çϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ´ÜÀÏ ¼¼Æ÷, ·Õ ¸®µå, °ø°£ ½ÃÄö½ÌÀÇ ±â¼ú ¹ßÀüÀº ŰƮÀÇ ¼º´É°ú ƯÀ̼ºÀÇ ÇѰ迡 µµÀüÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ ¼öÀÇÇÐ, ³ó¾÷, ȯ°æ À¯ÀüüÇÐ ºÐ¾ß¿¡¼­´Â ºÐ»êÇü °Ë»ç°¡ È®´ëµÇ¸é¼­ ÇöÀå ´ëÀÀÇü ŰƮ¿¡ ´ëÇÑ »õ·Î¿î ¼ö¿ä°¡ »ý°Ü³ª°í ÀÖ½À´Ï´Ù. ½ÃÄö½ÌÀÌ »ý¹°ÇÐ, ÀÇÇÐ, ³ó¾÷ÀÇ Áß½ÉÃàÀ¸·Î ÀÚ¸® ÀâÀ¸¸é¼­ À̸¦ Áö¿øÇϴ ŰƮ »ýŰ赵 ºü¸£°Ô È®ÀåµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(ÇÙ»ê ÃßÃ⡤ÁõÆø, ¶óÀ̺귯¸® Á¶Á¦, ÄÁÆ®·Ñ), ±â¼ú(NGS, »ý¾î), ¿ëµµ(Drug Discovery, Á¾¾çÇÐ, »ý½Ä ÀÇ·á, °¨¿°Áõ), ÃÖÁ¾ ¿ëµµ(Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö, º´¿ø¡¤Áø´Ü ¿¬±¸¼Ò, Çмú¡¤¿¬±¸±â°ü, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÇÕ°è 32 ÁÖ¸ñ)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»±¹, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÔ¿ø°¡ Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª°ú °ü¼¼ÀÇ ¿µÇ⠺м® :

¹Ì±¹ <>Áß±¹ <>¸ß½ÃÄÚ <>ij³ª´Ù <>EU <>ÀϺ» <>Àεµ <>±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·® °æÁ¦ »óȲÀÇ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Sequencing Kits Market to Reach US$19.2 Billion by 2030

The global market for Sequencing Kits estimated at US$12.9 Billion in the year 2024, is expected to reach US$19.2 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Nucleic Acid Extraction & Amplification, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$12.5 Billion by the end of the analysis period. Growth in the Library Preparation segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.5 Billion While China is Forecast to Grow at 11.0% CAGR

The Sequencing Kits market in the U.S. is estimated at US$3.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.0 Billion by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global "Sequencing Kits" Market - Key Trends & Drivers Summarized

Why Are Sequencing Kits Central to Genomics and Precision Medicine?

Sequencing kits are essential components in DNA and RNA analysis workflows, providing the reagents and protocols needed to prepare, amplify, and decode genetic material. These kits support a wide range of applications including whole genome sequencing, targeted gene panels, epigenetic profiling, and metagenomics. Whether used in clinical diagnostics, oncology research, or agricultural biotechnology, sequencing kits streamline complex workflows and ensure consistent results. Advances in next-generation sequencing (NGS) have made these kits even more critical, as higher throughput platforms require high-fidelity, low-contamination reagents to process thousands of samples efficiently. Additionally, with the rise of consumer genomics, microbiome testing, and infectious disease surveillance, sequencing kits are now used not only in elite research labs but also in decentralized and point-of-care settings. Their versatility and role in unlocking genetic information make them indispensable in the era of precision medicine.

Are Innovations in Library Prep and PCR Driving Kit Evolution?

Sequencing kits have evolved beyond basic reagent bundles into sophisticated, enzyme-optimized platforms. Innovations in library preparation kits have reduced input DNA requirements, enabled automation, and supported fragmented or degraded samples. PCR-free workflows are now available to minimize amplification bias, while dual-index adapters enhance multiplexing without compromising accuracy. Enzyme enhancements have also reduced reaction times, increased specificity, and minimized background noise. Single-cell sequencing kits, long-read sequencing reagents, and methylation-specific prep kits are expanding the technology’s reach into new biological domains. As researchers seek to study rare variants, complex structural variations, and cell-specific expression patterns, kit providers are responding with tailored, high-performance chemistry. Pre-loaded cartridges, lyophilized reagents, and room-temperature-stable formats are also enabling easier handling and shipping, especially in field diagnostics and mobile lab environments.

How Are Regulation and Clinical Integration Reshaping Kit Design?

As sequencing expands into regulated clinical diagnostics-such as non-invasive prenatal testing (NIPT), oncology companion diagnostics, and pathogen genome tracing-sequencing kits are undergoing stricter standardization and validation. Manufacturers are now developing IVD-grade kits compliant with FDA, CE-IVDR, and other national regulatory requirements. This includes pre-validated workflows, traceability, and lot-to-lot consistency in reagents. Kits are being co-developed with sequencing platforms to ensure end-to-end compatibility and reduce workflow errors. Integration with laboratory information systems (LIS) and automated liquid handlers is also becoming critical for CLIA-certified and hospital-based labs. Furthermore, reimbursement-linked diagnostics are pressuring developers to improve efficiency and reduce cost per sample. These clinical applications are transforming sequencing kits from research tools into critical, certifiable components of medical workflows, prompting higher manufacturing standards, better technical support, and increased focus on compliance documentation.

What’s Fueling Global Growth in the Sequencing Kits Market?

The growth in the global sequencing kits market is driven by several factors including rising genomic research funding, clinical adoption of NGS, and innovations in sequencing chemistry. Expanding national genomics initiatives across the U.S., China, UK, and Middle East are generating bulk demand for high-quality, cost-efficient kits. The integration of sequencing in oncology, rare disease diagnosis, and infectious disease surveillance-particularly post-COVID-has made standardized, validated kits essential for clinical labs. Academic institutions, CROs, and pharma companies are scaling up sequencing-based discovery programs, requiring a range of specialized reagent kits. Meanwhile, technological advancements in single-cell, long-read, and spatial sequencing are pushing the limits of kit performance and specificity. Growth of decentralized testing, especially in veterinary, agricultural, and environmental genomics, is creating new demand for field-compatible kits. As sequencing becomes a core pillar of biology, medicine, and agriculture, the supporting kit ecosystem is expanding rapidly to keep pace.

SCOPE OF STUDY:

The report analyzes the Sequencing Kits market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Nucleic Acid Extraction & Amplification, Library Preparation, Control); Technology (NGS, Sanger); Application (Drug Discovery, Oncology, Reproductive Health, Infectious Diseases); End-Use (Pharmaceutical & Biotechnology, Hospital & Diagnostic Laboratories, Academic & Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â